

Offers

We are currently in a position to offer you the following acquisition and licensing opportunities:

I. Acquisition opportunities

(Companies and products with established sales)

Project		Short Description
1.	Company in CEE for sale	<p>A company active in CEE region with subsidiaries is available. The company is the ideal platform to enter this market. They have a wide range of products in various indications and an excellent reputation at the physicians. (ID: MC-0470)</p> <p>Countries: CEE Turnover: > €50 million</p>
2.	Generic company	<p>A small but fast growing Spanish generic pharmaceutical company is looking for capital from a new investor. Ideally a pharmaceutical supplier with extensive generic portfolio, to support its strategy and business plan. The company plans to boost its operation and growth phase with portfolio expansion, tenders participation and promotion activities.</p> <p>This is an ideal platform to enter the Spanish or European attractive pharma market. (ID: MC-0434)</p> <p>Countries: Spain Turnover: < €1 million</p>
3.	OTC / Food supplement	<p>A small-sized OTC/food supplement company with own products and CDMO service is up for sale. The profit has grown steadily in recent years. The export of the products is growing and currently active in 5 countries. (ID: MC-0423)</p> <p>Countries: Baltic States Turnover: < €0,5 million</p>
4.	CRO Eastern Europe	<p>A small but experienced CRO in Eastern Europe for early clinical studies from Phase I to IIa is up for sale. (ID: MC-0416)</p> <p>Countries: Romania</p>

Project		Short Description
5.	Company in South America for sale	<p>A pharmaceutical company with GMP oncology injectable production plant is for sale. Indications: HIV/Oncology/Onco hematology and others! Own sales force and strong position in antiviral market. (ID: MC-0465)</p> <p>Countries: South America Turnover: > USD30 million</p>
6.	Company in LATAM for sale	<p>A company specialised in OTC and dietary supplements with own production is for sale. Focus on skincare, body and hair through pharmacy channel. Very attractive EBITDA. (ID: MC-0466)</p> <p>Countries: LATAM Turnover: > USD10 million</p>
7.	Company in LATAM for sale	<p>Focus on development, manufacture and marketing of vaccines and health products for women e.g. vaginal ovules, contraceptives and other women's health products, such as folic acid. About 22% of the company's revenue comes from exports, 25% from third-party manufacturing, and 53% from pharmaceutical business, of which 30% from women's health business. Sales force of 22 representatives, optimizing the target of doctors visited! Production facility (injectable, semisolids and biological) is not for sale but maybe negotiable. (ID: MC-0467)</p> <p>Countries: LATAM Turnover: > USD10 million</p>
8.	Company in Argentina for sale	<p>Most important therapeutic lines are: Musculo-skeletal apparatus, venous system, psychotropic, ophthalmology and feminine health. Exclusive representatives of special laboratory products from third parties. Production plant 1,600 m2 distributed in 3 levels, recently remodeled and in excellent condition. Quality Control department with modern equipment and qualified professional staff. The laboratory can sell its commercialized trademarks, approved certificates and its business permits, with or without its other assets (pharmaceutical plant, drugstore, offices). (ID: MC-0468)</p> <p>Countries: Argentina Turnover: > USD4 million</p>

Project		Short Description
9.	Company in Argentina for sale	<p>Medium-sized company, with an excellent positioning in the medical industry. Focused on psychiatry, neurology, hematology, gastroenterology, gynecology, urology and dermatology. Approximately 50 products, about 90 presentations. Productive plant with a capacity of approx. 25 M tablets-capsules/month. Staff of about 100 employees including marketing and sales reps. Acquisition with or without plant/production is possible. (ID: MC-0469)</p> <p>Countries: Argentina Turnover: > USD10 million</p>
10.	Italian company for sale	<p>A specialised company that sells prescription drugs and physician-driven OTC-products. In addition to the GPs the sales force visits Specialist-groups. The company is profitable and is ideal for a company that intends to enter the Italian market. (ID: MC-0386)</p> <p>Countries: Italy Turnover: < €20 million</p>
11.	Medium-sized company in Benelux for sale	<p>This medium-sized company in Benelux is for sale. The company is a pure marketing organisation without manufacturing facilities but with an own field force. It is an ideal platform for this region. (ID: MC-0011)</p> <p>Countries: Benelux Turnover: < €15 million</p>
12.	OTC portfolio and Company in Poland	<p>An OTC portfolio or the whole company is up for sale in Poland.</p> <p>The portfolio consists of a number of well-known branded food supplements with established sales. They are suitable for the following indications: gastroenterology, allergy and osteoporosis (ID: MC-0241)</p> <p>Countries: Poland Turnover: > €10 million</p>

Project	Short Description
13. Turkish pharmaceutical company with a large production facility for sale	<p>A Turkish pharmaceutical company with its own large production facility is up for sale. The company has its own marketing and sales organisation and also carries out contract manufacturing work.</p> <p>Being a CMO, it works for both national and international clients and manufactures solid, semi-solid and liquid products (film coated tablets, capsules, dry powder medications, creams, gels, lotions and syrups) (ID: MC-0232)</p> <p>Countries: Turkey Turnover: < €30 million</p>
14. Small company in Argentina	<p>A company is up for sale in Argentina. This firm specializes in a number of very interesting market segments with high price products. (ID: MC-0257)</p> <p>Countries: Argentina Turnover: < €10 million</p>
15. OTC companies in Germany	<p>A number of OTC companies are up for sale in Germany. Details on request. (ID: MC-0324)</p> <p>Countries: Germany Turnover: < €20 million</p>
16. OTC company in Austria with its own sales force	<p>A small well-established OTC company is up for sale in Austria. It sells its products via pharmacies and has its own sales force. (ID: MC-0301)</p> <p>Countries: Austria Turnover: < €10 million</p>
17. OTC company	<p>A small OTC company with an established product portfolio and low turnover is up for sale. This firm is particularly suitable for companies looking to expand their portfolio or their general business set-up. (ID: MC-0210)</p> <p>Country: Germany Turnover: < €1 million</p>
18. Small OTC company	<p>A small OTC company, whose products are sold almost exclusively via pharmacies, is up for sale. Its portfolio primarily contains food supplements. (ID: MC-0282)</p> <p>Country: Germany Turnover: < €2 million</p>

Project		Short Description
19.	Small OTC company in Austria	<p>A small OTC company with well-established products and a stable turnover is up for sale in Austria. (ID: MC-0302)</p> <p>Country: Austria Turnover: < €3 million</p>
20.	OTC Brand	<p>A well-known OTC product in the area of CNS is up for sale in Poland. (ID: MC-0462)</p> <p>Countries: Poland Turnover: approx. €1 million</p>
21.	OTC Package	<p>A basket of herbal products / brands are for sale in Russia and CEE. Also individual product acquisition is possible. (ID: MC-0464)</p> <p>Countries: Russia and CEE Turnover: > €10 million</p>
22.	Hansapharm	<p>Small pharmaceutical company with a very good established name Hansapharm is for sale. The owner comes from another industry and does not want to concentrate his activities on the pharmaceutical sector. Hansapharm sells high quality cosmetics, natural remedies and food supplements.</p> <p>The unique products and recipes such as MÖNCH BALSAM, NATURADOL, PIM BEINFLUID, JOHANNIFIT, SCHOKOVITA and MAMINKA are included in the package. The first three products are still on the market. The other products are available as a recipe with brand names. Preferably, the GmbH should be sold with all assets, but it is also possible to buy one or more products. (ID: MC-0422)</p> <p>Countries: Germany Turnover: < €100 k</p>
23.	Migraine-Brand	<p>An excellent trademark for a migraine remedy is available. The brand is very inculcating and ideal for an OTC drug with its nice sounding name. (ID: MC-0457)</p> <p>Countries: Germany</p>
24.	Herpes Labialis	<p>New innovative product for the treatment of cold sores is for sale. There is no direct generic competition (new substance). It is an OTC medicinal product. (ID: MC-0458)</p> <p>Countries: Spain, Portugal, Germany</p>

Project		Short Description
25.	OTC Brand	<p>An OTC product in the area of CNS is up for sale in Scandinavia. (ID: MC-0463)</p> <p>Countries: Scandinavia Turnover: < €1 million</p>
26.	Medical device	<p>A new, patented medical device has been developed for easy handling with maximum effectiveness and reduction of components (very cost efficiency). The single-dose inhaler can be represented as reusable inhaler or disposable inhaler on blister base. It is a nasal and oral inhaler. Advantages: no capsule, no splinters, simple, intuitive operation, easy to clean, it allows for the simultaneous release of two different drugs (tandem). Application for acute short term/ chronic or long term treatments. Asthma, antibiotics, COPD, CF, pain, migraine, depression, burnout, infections (bacterial, viral), cancer therapy, hormone therapy, others replacement for traditional multi-dose devices to reduce cost e.g. in emergency rooms, ambulances, short time hospitalization. The medical device can be purchased / acquired or also in-licensed. (ID: MC-0461)</p>
27.	Dementia	<p>A CNS product with existing sales for patients with dementia syndrome in primary degenerative, vascular dementia and mixed forms, can be purchased. (ID: MC-0366)</p> <p>Countries: Germany, Austria and Hungary</p>
28.	Gastroenterology	<p>A medical device as a chewable tablet for the treatment of reflux / acid regurgitation can be purchased or exclusively licensed. (ID: MC-0381)</p> <p>Countries: Europe</p>
29.	OTC gastroenterology product	<p>A small 'pharmacy-only' product is up for sale. Targeted in the field of gastroenterology with stable sales for many years. (ID: MC-0332)</p> <p>Countries: Germany Turnover: < €100 k</p>
30.	Cold/Sniff	<p>2 marketing authorisations of an OTC nasal spray with Xylometazoline are up for sale, with or without production binding. (ID: MC-0391)</p> <p>Countries: Germany</p>

Project		Short Description
31.	Urology	<p>Prescription medicine brand with existing sales in the field of urology can be purchased. The substance is generic but with slightly increasing sales. (ID: MC-0392)</p> <p>Countries: Germany Turnover: < €120 k</p>
32.	Gynaecology	<p>An OTC product / registration without production binding for magnesium deficiency in a high dosage is for sale. (ID: MC-0400)</p> <p>Countries: Germany</p>
33.	Old original brands	<p>Some mature brands in Rx and OTC in different indications are for sale. Also one innovative patented product in Europe with growth. (ID: MC-0367)</p> <p>Countries: different countries, worldwide Turnover: on request</p>
34.	Weight loss product range	<p>A branded product range is up for sale. It is targeted at the weight loss market and consists of food supplements and complementary products. (ID: MC-0279)</p> <p>Countries: Germany Turnover: < €1 million</p>
35.	Cardiovascular/OTC	<p>A very well-known brand in Germany is for sale. The brand has stable sales under 3 million Euros and was in the past in the pharmacy, but over the years the brand has become available in drug stores. The brand would be the ideal umbrella-brand for other products in drug stores or in the pharmacy. (ID: MC-0377)</p> <p>Countries: Germany</p>

II. Licensing opportunities

(Marketing rights and R&D cooperation opportunities)

Project		Short Description
Allergy		
36.	Allergic patch test system	Licences for an allergic patch test system for diagnosis of allergy are available. Target groups are the allergists and dermatologists. (ID: MC-0383) Countries: Canada, South Korea
37.	Allergy	Licences for symptoms of ocular seasonal allergic rhinitis are available. (ID: MC-0349) Countries: on request
38.	Allergy	An exclusive licence is available for a medicine that is used to treat allergic rhinitis and itching; there is no direct competitor (protected by patent). (ID: MC-0351) Countries: on request
Central nervous system		
39.	Alzheimer's disease	For a rivastigmine patch for the treatment of Alzheimer's disease licences are available in individual countries in the EU. (ID: MC-0452) Countries: Spain, France, Italy, Scandinavia
40.	Acute Migraine	An exclusive licence for multiple regions or countries in Europe, Asia or South America for a patented migraine product is available. New is the combination of two well-known active substances, so that there is a faster onset of action and only once a day. (ID: MC-0444) Countries: Europe, South America, Asia
41.	Restless Legs Syndrome	An exclusive licence for Europe is available for a new medicinal product in RLS (Restless Legs Syndrome) which is already successfully marketed in some countries (ID: MC-0443) Countries: Europe

Project		Short Description
42.	Orphan Drug / Niche product	For an Orphan Drug in CNS indication is an exclusive licence available in certain countries in the EU. The developer would like to keep the licence only in his home country. It is a niche product with a small target group of specialists. Sales potential in Europe between 20 and 30 million euros. (ID: MC-0436) Countries: several countries in Europe
43.	Parkinson's disease	Exclusive licence with limited competition for the treatment of Parkinson's disease is available. It is an injection. (ID: MC-0427) Countries: Germany, UK and Ireland
44.	Epilepsy	Exclusive licences for a prescription only product with a USP for the treatment of epilepsy are available. Tablets are smaller and with a much higher dose (once daily). (ID: MC-0405) Countries: worldwide
45.	Migraine	An exclusive licence for the treatment of migraine is available. This auto injector is used to treat acute migraine with or without aura, and acute cluster headaches in adults. The advantage is the faster onset of action and the evasion of the stomach intestinal tract. (ID: MC-0376) Countries: worldwide
46.	Migraine	An exclusive licence in the field of CNS for the treatment of migraine is available. It is a patented new formulation which hasn't been introduced in Europe yet. The European Marketing Authorization will be valid soon. The substance is generic but has certain USP's like the faster onset of action. (ID: MC-0374) Countries: several countries in Europe
47.	Insomnia	An exclusive licence for innovative, patented preparation for the treatment of insomnia for children is available. Partner with distribution and promotion power to CNS specialists and/or paediatricians preferred. (ID: MC-0043) Countries: Benelux, China, Japan and USA

Project		Short Description
48.	Anaesthetic	<p>A licence is available for the distribution of a product (muscle relaxant) used to facilitate intubation.</p> <p>The product is subject to production commitments. (ID: MC-0251)</p> <p>Countries: I, NL, AT, PL</p>
49.	Migraine	<p>Licences are available for a new dosage form of a generic drug for treating migraines. (ID: MC-0097)</p> <p>Countries: several Countries in Europe</p>
50.	Drug addiction treatment	<p>An exclusive licence is available for methadone in the Netherlands. Its dosage form is particularly interesting and has an advantage over its competitors' products. It can also be used to treat pain. (ID: MC-0121)</p> <p>Countries: The Netherlands</p>
51.	Treatment of neurological and cognitive disorder	<p>An exclusive licence is available for a medicine for treating acute strokes; it faces limited direct competition. (ID: MC-0350)</p> <p>Countries: on request</p>
Dermatology		
52.	Small portfolio	<p>Small portfolio in Dermatology and Gynaecology for exclusive licence in Germany available. The portfolio are prescription only products with existing sales and existing MA's. (ID: MC-0435)</p> <p>Countries: Germany</p>
53.	Skin infection	<p>An exclusive licence for an innovative medical product is available. The product is used for bacterial skin infections in adults and mainly in children. The Product stands out due to its safety and tolerability. The product is launchable right away. (ID: MC-0441)</p> <p>Countries: Germany, Belgium, Netherlands, Finland, Sweden, Poland, UK and Ireland</p>
54.	Aesthetic portfolio	<p>An aesthetic portfolio including botulinum toxin is available for exclusive licensing in single countries and regions.(ID: MC-0398)</p> <p>Countries: on request</p>

Project		Short Description
55.	Hair loss	<p>Exclusive licence to treat hair loss. The patented product is herbal based and underpinned with clinical trials. It is a dermocosmetic which can be promoted directly at the specialists and patients. (ID: MC-0385)</p> <p>Countries: on request</p>
56.	Dermocosmetics	<p>An exclusive licence for a broad portfolio of dermocosmetics is available. The licensee can use his own brands or an umbrella brand. The portfolio is for babies, children and adults and already successfully launched in different countries, among them Germany. It would be the ideal platform for companies who are not active in this field and therefore need a whole range of products. (ID: MC-0375)</p> <p>Countries: every country worldwide except Germany, Spain</p>
57.	Atopic dermatitis	<p>A class IIa medicinal product is available as an auxiliary treatment for atopic and allergic dermatitis presenting as dry, fragile and sensitive skin. The product is also recommended for treating nappy rash. The main ingredient is made specifically for this product. A short presentation is available on request; no additional steps are necessary. (ID: MC-0226)</p> <p>Countries: Germany</p>
58.	Skin lesions	<p>A licence is available for a class IIa medicinal product for preventing and relieving skin lesions caused by diabetes, pressure ulcers or maceration resulting from incontinence. The main ingredient is made specifically for this product. A short presentation is available on request; no additional steps are necessary. (ID: MC-0225)</p> <p>Countries: Germany</p>
59.	Herpes simplex	<p>An innovative topical acyclovir formulation for the treatment of herpes simplex. This class III medical product has a number of advantages. (ID: MC-0307)</p> <p>Countries: Europe</p>

Project		Short Description
60.	Hyperkeratosis product	<p>A product is available for the treatment of hyperkeratosis. Its innovative formulation ensures that the active ingredients remain in the treatment area and so are effective for several hours. (ID: MC-0305)</p> <p>Countries: Germany, more on request</p>
61.	Rx dermatology product	<p>Licences are available for an innovative medicine for treating primary and secondary skin infections. Specific tests were carried out to check the efficacy of the product as a treatment for children suffering from primary skin infections. It is therefore an interesting prospect for companies visiting both dermatologists and paediatricians. (ID: MC-0289)</p> <p>Countries: Europe</p>
62.	Mosquito bites	<p>A clinically and dermatologically tested cosmetic product to reduce the itching caused by mosquito bites. A user-friendly administration method. (ID: MC-0308)</p> <p>Countries: Europe</p>
63.	Patented herpes simplex product	<p>A patented and innovative acyclovir formulation is available, which – among other things – treats herpes much faster than its competitors' products. (ID: MC-0304)</p> <p>Countries: Germany, further countries on request</p>
64.	Burns, bedsores	<p>A licence is available for a medicinal product with its own USP for the treatment of first and second degree burns. (ID: MC-0052)</p> <p>Countries: Germany, UK and other European countries on request</p>
65.	Product for healing wounds	<p>Licences are available for a class III medical product for the treatment of skin injuries (e.g. lesions, burns, abrasions). (ID: MC-0309)</p> <p>Countries: Europe</p>

ENT		
66.	Otology	<p>A licence for an innovative unique Rx product for the treatment of Inflammation in the ear is available. (ID: MC-0439)</p> <p>Countries: France, Spain, Germany, Finland, Norway, Denmark, Sweden and Italy</p>
Food Supplements		
67.	Different Indications	<p>Patented capsule, which stomach release and intestinal release. Different nutritional supplements in different indications such as dermatology, gynecology, CNS, gastroenterology and cardiovascular. Already developed with clinical trials and often higher concentration than all pharmaceutical alternatives. (ID: MC-0453)</p> <p>Countries: on request</p>
68.	Paediatrics, Woman's Health, General Wellbeing	<p>We offer a licence for a range of food Supplements. Indications: Pediatrics, Woman's Health, General Wellbeing. (ID: MC-0406)</p> <p>Countries: EU and others upon request</p>
69.	Diabetes	<p>Licences for the dietary treatment of glucose metabolism disorders are available. The food supplement is for diabetes type 2. (ID: MC-0384)</p> <p>Countries: worldwide, expect USA, Canada and Germany</p>
70.	Metabolism	<p>Licences for an innovative Food Supplement are available. (ID: MC-0347)</p> <p>Countries: on request</p>
Gastroenterology		
71.	Ulcerative colitis	<p>Licences for the treatment of mild to moderately active ulcerative proctitis are available. The dosage forms are suppositories. (ID: MC-0382)</p> <p>Countries: worldwide, individual countries, regions</p>
72.	Fatty liver	<p>For a novel dietary food for special medical purposes (balanced diet) that helps to lower elevated liver values licences are available. (ID: MC-0371)</p> <p>Countries: Europe</p>

73.	Heartburn	<p>A medical device as a chewable tablet for the treatment of reflux / acid regurgitation can be purchased or exclusively licensed. (ID: MC-0381)</p> <p>Countries: Europe</p>
74.	Functional diagnostics	<p>This Rx product is used to facilitate functional diagnostics. It contains an active ingredient that has already demonstrated its efficacy and safety in another indication area. (ID: MC-0175)</p> <p>Countries: Europe</p>
75.	Intestinal disorders	<p>Exclusive licences are available for an anti-spasmodic agent (both Rx and OTC) which directly affects the muscle of the digestive tract. (ID: MC-0222)</p> <p>Countries: several Countries in Europe</p>
76.	Stomach / intestinal disorders	<p>A dossier and licence are available for an Rx and OTC medicine for treating stomach and intestinal disorders, such as irritable bowel syndrome, diarrhoea, intestinal cramp and constipation. (ID: MC-0330)</p> <p>Countries: Germany and Scandinavia</p>
77.	Pilonidal sinus/Crohn's Disease	<p>An innovative topical formulation used to provide effective pain relief, reduce discharge and improve healing rates in patients with pilonidal sinus. (ID: MC-0148)</p> <p>Countries: worldwide</p>
78.	Reflux product	<p>A class IIa medical product is available for relieving heartburn. It only contains natural ingredients. A short presentation is available upon request. (ID: MC-0303)</p> <p>Countries: Germany, more on request</p>
79.	Synbiotic product	<p>Licences are available for a symbiotic product which involves patented technology and offers patients a number of benefits. (ID: MC-0318)</p> <p>Countries: Belgium, France, Spain, Netherlands, Portugal, UK, Italy and other countries around the world on request</p>

Gynaecology		
80.	Vaginal Dryness/Atrophy	<p>Exclusive licence of a medical device in the form of a vaginal gel for the treatment of vaginal dryness and vaginal atrophy during pregnancy or menopause is available. (ID: MC-0450)</p> <p>Countries: nearly all countries available</p>
81.	Atrophy/Infection	<p>Exclusive licences for the treatment of vaginal atrophy and prevention of local infections are available. The medical device is patented. (ID: MC-0419)</p> <p>Countries: worldwide</p>
82.	Bladder Infections	<p>Exclusive licences can be purchased for a medicinal product which is used for the treatment of the inflammation of the bladder (Cystitis), Cystoscopy, hyperactive urinary bladder, etc. (ID: MC-0046)</p> <p>Countries: on request</p>
83.	Syphilis	<p>Exclusive licence for the treatment of syphilis is available. It is a niche product and a growing market because of the refugees and immigrants. (ID: MC-0387)</p> <p>Countries: individual countries on request</p>
84.	Nutrient deficiencies	<p>A licence for a food supplement product against micronutrient deficiencies during pregnancy and lactation is available. (ID: MD-0361)</p> <p>Countries: worldwide</p>
85.	Nausea/Vomiting	<p>A licence for a dietary supplement for nausea and vomiting during pregnancy is available. (ID: MD-0362)</p> <p>Countries: worldwide</p>
86.	Osteoporosis	<p>An exclusive licence is available for a prescription-only vitamin D3 product which has a number of advantages over conventional vitamin D3 suppliers. The product is used to treat osteoporosis and vitamin D3 deficiency. (ID: MD-0352)</p> <p>Countries: on request</p>
87.	Contraceptives	<p>Licences are available for a wide range of contraceptives. (ID: MC-0256)</p> <p>Countries: AT, BE, CZ, DE, ES, FR, HU, IT, NL, PL, PT, RO, UK</p>

88.	Bacterial and mycotic infections	<p>We offer an exclusive licence for a probiotic used as co-adjuvant for the bacterial and mycotic infections treatment in order to restore the vaginal flora. The product is offered in 2 different dosage forms. (ID: MC-0062)</p> <p>Countries: on request</p>
89.	Menopause	<p>An exclusive licence is available for a food supplement used as an auxiliary treatment for relieving menopausal symptoms. (ID: MC-0199)</p> <p>Countries: Europe (countries on request)</p>
90.	Nausea and vomiting during pregnancy	<p>An exclusive licence is available for a food supplement; an effective alternative to treating nausea during pregnancy. (ID: MC-0200)</p> <p>Countries: Europe (countries on request)</p>
91.	Problems with breastfeeding - sore and cracked nipples	<p>A class IIa medicinal product is available for preventing and easing sore and cracked nipples. The main ingredient is made specifically for this product. The efficacy of the product is backed up by the results of clinical studies. A short presentation is available on request; no additional steps are necessary. (ID: MC-0227)</p> <p>Countries: Germany</p>
92.	Urinary tract infection	<p>An exclusive licence is available for a food supplement used to prevent the recurrence of urinary tract infections in women. (ID: MC-0197)</p> <p>Countries: Europe (countries on request)</p>
93.	Vaginal wash	<p>This patented class I medicinal product reduces itching and prevents infection. As it is made with natural ingredients, it can be used when taking other drugs. Midwives frequently recommend this product during pregnancy and especially during the months following childbirth to soothe any feelings of discomfort and improve hygiene. (ID: MC-0136)</p> <p>Countries: Europe</p>

Nephrology

94.	Kidney insufficiency	<p>Exclusive licence available for a dietary food for special medical uses in patients with chronic kidney disease who are malnourished or at risk of malnutrition. Complete normal-protein high-calorie diet with fibre in powder format. Has already been successfully launched in one country. The product is reimbursed and has a unique composition. (ID: MC-0454)</p> <p>Countries: worldwide</p>
95.	Hyperparathyroidism	<p>Exclusive licence for a generic Cinacalcet indicated for treating hyperparathyroidism is available. The original has a solitary position, it is the only calcimimetic drug. Sales in EU approx. 150 million €. (ID: MC-0429)</p> <p>Countries: different countries in Europe</p>
96.	Hyperphosphatemia	<p>Sevelamer Carbonate indicated for treating hyperphosphatemia in chronic renal insufficient patients - exclusive licence available. Manufacturing of finished product at European GMP certified site. (ID: MC-0430)</p> <p>Countries: different countries in Europe</p>
97.	Iron Sucrose Product	<p>Exclusive licence is available of an iron sucrose product indicated for parenteral substitution of iron i.v. in patients with iron deficiency or iron deficiency anemia to be distributed in potential EU territories. Current manufacturing of API and finished product at European GMP certified site. The originator has sales of 110 million €. (ID: MC-0431)</p> <p>Countries: different countries in Europe</p>

Oncology

98.	Breast and Gastric Cancer	<p>An exclusive licence for a late state biosimilar used for the treatment of breast and gastric cancer is available. The substance is Trastuzumab. (ID: MC-0442)</p> <p>Countries: on request</p>
-----	----------------------------------	---

99.	Generic Hospital Product	For a generic hospital product, exclusive licences can be purchased. The patent of the originator will expire in 2019, so that you could introduce/launch immediately. The originator generates in the EU about 20 million euros sales. (ID: MC-0437) Countries: different countries
100.	Bladder Cancer	Exclusive licences for a diagnosis test for bladder cancer is available. It is an innovative Medical Device with the aim to reduce the painful invasive procedure of cystoscopy. (ID: MC-0410) Countries: Europe, except Italy, Spain, Scandinavia, Czech and Slovakia
101.	Chemotherapy/Pain	An exclusive licence for an innovative medicinal device to treat oral mucositis is available. Oral mucositis is a painful inflammation which is often a serious side effect of cancer treatments (radiation and chemotherapy). The focus is on pain management. The advantage is the fast onset of action in 5 minutes and pain relief for up to 8 hours. (ID: MC-0368) Countries: on request
102.	Nephrology	An exclusive licence of the biosimilar (Darbepoetin alfa) is available for Europe. (ID: MC-0369) Countries: Europe
103.	Leukaemia	Licenses for the treatment of acute myelogenous and acute lymphatic leukemia are available. There is no direct competitor in these countries. (ID: MC-0346) Countries: Poland, Spain, Czech Republic and Slovakia
104.	Familial adenomatous polyposis (FAP)	An innovative chemo preventive agent for the long-term treatment of FAP patients. Phase IIB studies have been completed successfully. (ID: MC-0146) Countries: All countries except France, Germany, Italy, Spain and the UK
105.	Liver cancer	An exclusive licence is available for a niche oncology product for the treatment of liver cancer. (ID: MC-0326) Countries: Europe and USA

106.	Niche oncology product	An exclusive licence is available for a niche oncology product (injection) for treating a subtype of leukaemia. The product has been granted orphan drug status. (ID: MC-0325)
		Countries: Emerging Markets
Ophthalmology		
107.	Eye Inflammation	An exclusive licence for an innovative drug for the treatment of eye inflammation is available. Faster efficacy, longer effect, preservative free, easy handling and very high potency anti-inflammatory. It is still under development and is expected to be launched in 2020. (ID: MC-0455)
		Countries: on request
108.	Medical Device	A licence for a medical device product in the field of ophthalmology is available. The product is used in the treatment of dry eyes, It has a new formula and it is planned to be on the market in 2020. (ID: MC-0440)
		Countries: on request
109.	Glaucoma/ocular Hypertension	For a product with a USP for the treatment of glaucoma and ocular hypertension licences are available. It is Latanoprost BAK free. (ID: MC-0404)
		Countries: worldwide
110.	Macular degeneration	Licences for an innovative food for the dietary treatment of age-related macular degeneration (AMD) and homocysteine-associated circulatory disorders of the eye are available. (ID: MC-0370)
		Countries: Europe
111.	Ophthalmology licences	Licences are available for ophthalmology medical products and food supplements for treating a variety of eye conditions as well as macular degeneration. (ID: MC-0314)
		Countries: Germany and other western European markets upon request
112.	Antibiotics	Licences for a fluorinated carboxyquinolone anti-infective for topical ophthalmic use are available (ID: MC-0348)
		Countries: on request

113.	Retina protection	An exclusive licence is available for a food supplement used to prevent age related macular diseases. (ID: MC-0198)
		Countries: Europe (countries on request)
Other products		
114.	Obesity	A prescription only product for the treatment of obesity can be licensed in Germany, Austria and France. In addition to the many nutritional supplements, this product is a real alternative for patients who have already tried everything. More than 140 million people in Europe suffer from obesity and the numbers are rising steadily. The product is for adults who have a BMI over 30. The product is immediately marketable. (ID-MC-0438)
		Countries: Germany, Austria, France and Switzerland
115.	Anaesthesia	Licence available for distribution of a preparation used for facilitation of intubations. Product underlies production binding. (ID: MC-0424)
		Countries: on request
116.	Dyslipidaemia	Exclusive licence for a phase 3 product in different indications like: Dyslipidaemia for the treatment of high cholesterol and blood lipid levels and for the treatment of non-alcoholic fatty liver. (ID: MC-0411)
		Countries: worldwide
117.	Venous Thromboembolic	Licences are available for a drug of choice for prevention and treatment of Venous Thromboembolic disease. The product is currently in the market in 54 countries and in registration process in 16 additional countries. (ID: MC-0402)
		Countries: UK, Ireland, Portugal, Poland, Slovenia, South Africa and some ASEAN countries
118.	Metabolic disease	For the dietary treatment of increased homocysteine levels licences are available. (ID: MC-0372)
		Countries: Europe
119.	Metabolic disease	For the dietary treatment of elevated cholesterol, licences can be purchased. (ID: MC-0373)
		Countries: Europe

120.	Anaesthesia	<p>A licence is available for the distribution of a product for inducing anaesthesia. The product is subject to production commitments. (ID: MC-0250)</p> <p>Countries: I, NL, A, S, DK, N, B</p>
121.	Angina / hypertension	<p>Licences are available for a patented combination product. It is also possible to purchase marketing authorisations for several countries. (ID: MC-0319)</p> <p>Countries: Austria, Italy, Croatia, Belgium, Luxembourg</p>
122.	Biosimilar	<p>Licences are available for biosimilar for the following areas: anti-infectives, cardiovascular and hormones. (ID: MC-0337)</p> <p>Countries: Europe</p>
123.	Iron supplement	<p>License option for a highly bioavailable iron (dietary supplement) with good study situation, which is already being marketed successfully in a European country. Due to good study results, the preparation can also be well presented to specialists. (ID: MC-0269)</p> <p>Countries: Germany, Austria, Switzerland</p>
124.	Weight control / overweight	<p>This class III medicinal product is for general weight management as well as to prevent and treat overweight. The special form of the natural active ingredient is patented and the product's efficacy is backed up by clinical studies. A short presentation is available on request; no additional steps are necessary. (ID: MC-0230)</p> <p>Countries: Germany</p>
125.	Hospital product	<p>A licence is available for a hospital product used to treat newborns. A vitamin K dossier is available for national registration. (ID: MC-0105)</p> <p>Countries: Europe</p>
126.	Generics portfolio	<p>A generics company with a wide range of products that does not sell its medicines in France and Italy. This is an interesting opportunity for businesses looking to extend their own portfolio or even to set up their own business unit. It already has many marketing authorisations so the products can be launched immediately. (ID: MC-0357)</p> <p>Countries: Italy, France</p>

Paediatrics		
127.	Lice treatment	<p>A licence for an innovative medical device against lice is available. Top OTC product for the target group of paediatricians and pharmacies. It has been proven to work after 5 minutes. (ID: MC-0408)</p> <p>Countries: worldwide (except Canada, Australia, Israel, Japan, Germany)</p>
128.	Hypotension	<p>Exclusive licences for a hospital product in hypotension (paediatricians/neonatology) are available. The innovative product is in late stage development. (ID: MC-0403)</p> <p>Countries: Europe and US</p>
129.	Product group for baby & toddlers	<p>A licence is available for a bespoke portfolio of products for treating various indications in babies and toddlers (nappy rash, chapped skin, chesty cough, dry cough, blocked nose, sore throat, listlessness...). The formulation and dosage of the products have been adapted to suit the various age groups. (ID: MC-0312)</p> <p>Countries: Germany</p>
130.	Neonatology: Vitamin K deficiency bleeding	<p>A licence is available for a product to treat vitamin K deficiency bleeding in newborns. An exclusive licence is available for different countries inside the EU. The dossier has been updated for submission to the various national authorities. (ID: MC-0145)</p> <p>Countries: Europe</p>
Pain control		
131.	Ibuprofen Patch	<p>A new ibuprofen patch is available. The Phase 1 studies have just been completed. (ID: MC-0421)</p> <p>Countries: Europe</p>
132.	Hospital Product	<p>Exclusive licences for a hospital product indicated for acute, postoperative pain management in adults are available. In some countries with existing marketing authorisation. The innovation is not the substance but the application form. (ID: MC-0426)</p> <p>Countries: on request</p>

133.	Pain	<p>Exclusive licences for a topical pharmaceutical drug for acute and chronic pain is available. The USP is not the substance. It is the formulation which has a much faster onset of action. (ID: MC-0412)</p> <p>Countries: Europe except UK, Ireland, Spain, Portugal, France, Benelux, Belarus, Russia and Ukraine</p>
134.	Local Anaesthesia/Patch	<p>Exclusive licence available for a topical patch for local anaesthesia. This patch is a generic development with only one competitor. (ID: MC-0409)</p> <p>Countries: on request except France, UK, Sweden, Finland, Norway, Denmark</p>
135.	Pain	<p>Licences for a Buprenorphine patch for the treatment of chronic pain is available. (ID: MC-0122)</p> <p>Countries: Spain, France, Italy, Scandinavia</p>
136.	Cannabis	<p>Licences for a cannabis medical device product for advanced cancer pain are available. One product is a pharmaceutical drug in Phase III clinical trial and one is a quality-tested medicinal hemp. (ID: MC-0390)</p> <p>Countries: worldwide except USA and Canada</p>
137.	Oncology/Chemotherapy	<p>For an Oxycodone injection exclusive licences are available for certain territories. For the treatment of moderate to severe pain in patients with cancer and post-operative pain. (ID: MC-0388)</p> <p>Countries: Europe</p>
138.	Chemotherapy/Pain	<p>An exclusive licence for an innovative medicinal device to treat oral mucositis is available. Oral mucositis is a painful inflammation which is often a serious side effect of cancer treatments (radiation and chemotherapy).</p> <p>The focus is on pain management. The advantage is the fast onset of action in 5 minutes and pain relief for up to 8 hours. (ID: MC-0368)</p> <p>Countries: Europe (countries on request)</p>

139.	Herbal pain ointment	<p>This ointment is already being successfully marketed in a number of countries. It contains a high dose of an active ingredient extracted from a specific selection of medicinal plants. Thanks to this specific combination of ingredients, this ointment is able to regenerate tissue and heal wounds as well as alleviate pain. It has a higher dosage than its competitor products and an extremely low PA value (pyrrolizidine alkaloids). The efficacy and good tolerability of this product are backed up by several clinical studies. (ID: MC-0290)</p> <p>Countries: worldwide except Germany and Austria</p>
140.	Lower back pain	<p>A patented and innovative medicinal product for the treatment of lower back pain and many other conditions. (ID: MC-0178)</p> <p>Countries: Europe</p>
141.	Muscle relaxant	<p>Licences are available for a product used to treat painful muscle tension. (ID: MC-0102)</p> <p>Countries: Europe except Germany</p>
142.	Analgesic agent	<p>A licence is available for a patented innovative product used in the area of anaesthesia. Target groups are paediatricians, oncologists and nephrologists. (ID: MC-0098)</p> <p>Countries: Europe</p>
143.	Prescription-only painkiller	<p>An exclusive licence is available for a prescription-only painkiller. This new dosage form has a number of advantages. (ID: MC-0030)</p> <p>Countries: Belgium, Italy, Austria, Poland, France, Spain and Russia</p>
144.	Severe pain	<p>The active substance is a generic substance but the formulation is new to Austria. An exclusive licence is available for this product which already has a valid marketing authorisation. (ID: MC-0103)</p> <p>Countries: Austria</p>
Proctology		
145.	Chronic Anal Fissures	<p>Exclusive licenses are available for a unique prescription drug for the treatment of chronic anal fissures. (ID: MC-0459)</p> <p>Countries: on request</p>

146.	Anal fissures / Haemorrhoids	<p>Prescription-only medicinal drug for the treatment of anal fissures and haemorrhoids is available for exclusive licence in certain countries. It is already successfully marketed in different countries. (ID: MC-0428)</p> <p>Countries: worldwide</p>
147.	Anal fissure	<p>Innovative product to provide pain relief for patients with anal fissure. The product is as effective as current treatments but has a much improved safety profile. (ID: MC-0147)</p> <p>Countries: US, Canada, Middle East, Asia, Africa</p>
148.	Haemorrhoids	<p>This class IIa medicinal product is for the treatment of internal and external haemorrhoids and reduces pain, burning and itching. The main ingredient is made specifically for this product. The efficacy of the product is backed up by the results of clinical studies. A short presentation is available on request; no additional steps are necessary. (ID: MC-0229)</p> <p>Countries: Germany</p>
149.	Haemorrhoids / anal discomfort	<p>A medicinal product (class 1) for relieving and preventing haemorrhoids. This product has been successfully marketed in one country in Western Europe. Licences are now available for all other countries. (ID: MC-0189)</p> <p>Countries: several countries in Europe</p>
150.	Haemorrhoid product	<p>Exclusive licences are available for a medicinal product for the long-term treatment of patients with haemorrhoids. It protects the anal region, relieves complaints and eases bowel movement. Furthermore, it can be used during pregnancy and by mothers breastfeeding their children. (ID: MC-0092)</p> <p>Countries: Europe</p>

Respiratory illnesses

151.	Bronchitis / Allergic / COPD	<p>An exclusive licence of a medical device (hyaluronic acid) in the form of a sterile solution for inhalation for the treatment of bronchitis, allergic rhinitis and COPD is available. The target group are paediatricians, pulmonologists, APIs and pharmacists. (ID: MC-0451)</p> <p>Countries: nearly all countries free for licensing</p>
152.	Ear-Nose-Throat	<p>For an innovative Medicinal Device against snoring an exclusive licence is available. The product is clinically proven and the licensee could use his own trademark/brand. (ID: MC-0365)</p> <p>Countries: Europe (countries on request)</p>
153.	Asthma inhalers	<p>Different licences are available for generic developments of individual substances and combination products with their corresponding device. (ID: MC-0169)</p> <p>Countries: several European countries</p>
154.	Coughs and colds	<p>A licence is available for an OTC product for the treatment of coughs and colds. This drug has a new formulation and the dosage is much higher than the competitors' products. (ID: MC-0027)</p> <p>Countries: Germany, Poland, Czech Republic, Serbia and Spain</p>
155.	Respiratory disease	<p>An exclusive licence is available for an innovative prescription drug for the treatment of chronic bronchitis and COPD. It has been proven that the drug provides important clinical benefits when used to treat acute and chronic respiratory diseases in both adults and children. The product has already been successfully launched in more than 30 countries worldwide. An exclusive licence is available for Denmark. (ID: MC-0182)</p> <p>Countries: Germany, Denmark</p>
156.	Sore throat	<p>An OTC combination product for the treatment of sore throats. The product is already being successfully marketed in several European countries. A licence is currently available for Germany. (ID: MC-0026)</p> <p>Countries: Germany</p>

157.	Lozenges	<p>Distribution licences are available for lozenges containing different ingredients such as lidocaine, benzydamine and flurbiprofen. (ID: MC-0212)</p> <p>Countries: single countries in Europe on request</p>
Rheumatology		
158.	Arthritis	<p>Exclusive licenses are available for the treatment of rheumatological disorders, psoriasis and psoriatic arthritis, and for the maintenance treatment of acute lymphoblastic leukaemia. The innovative, patented product is developed just for children. (ID: MC-0401)</p> <p>Countries: Europe, Norway, Iceland and Liechtenstein</p>
159.	Anti-rheumatic agent (hyaluronic acid)	<p>Our client is looking for a European licence partner for his medicinal product class III which is used to substitute or supplement synovial fluid. The product is licensed for Osteoarthritis intra-articular use for treating degenerative joint diseases of the knee, hip, ankle, shoulder, elbow and fingers. The target group is orthopaedic specialists. An exclusive licence, including a trademark is available in nearly all regions or countries in Europe and worldwide. (ID: MC-0047)</p> <p>Countries: on request</p>
160.	Osteoporosis	<p>An exclusive licence is available for a prescription-only vitamin D3 product which has a number of advantages over conventional vitamin D3 suppliers. The product is used to treat osteoporosis and vitamin D3 deficiency. (ID: MC-0352)</p> <p>Countries: on request</p>

161.	Herbal product line for the treatment of acute soft tissue injuries as well as joint and muscle pain	<p>Licences are available for a product line consisting of three class IIa herbal medicine products and one food supplement. The range includes products for treating both acute and chronic disorders. One of the products uses spray-on technology and has an anti-bacterial effect for the treatment of minor injuries.</p> <p>The efficacy of the products is supported by the results of clinical studies (including a comparative study with a diclofenac gel). A short presentation is available on request. (ID: MC-0228)</p> <p>Countries: Germany</p>
162.	Hyaluronic acid injection for treating osteoarthritis	<p>Licences are available for a hyaluronic acid injection for treating osteoarthritis (competitive COG). It has been approved as a medicinal product across Europe. (ID: MC-0291)</p> <p>Countries: Germany, Italy, other countries worldwide on request</p>
Urology		
163.	Bladder pain	<p>An exclusive licence for the treatment of bladder pain is available. The product is innovative and unique with no direct competition. (ID: MC-0456)</p> <p>Countries: Italy, Poland</p>
164.	Nocturnal enuresis	<p>Registered product with galenic USP, for the treatment of diabetes insipidus centralis, and the treatment of primary nocturnal enuresis, can be licensed. (ID: MC-0288)</p> <p>Countries: worldwide except Spain, Greece, Portugal and Germany</p>
165.	Hormone therapy	<p>Testosterone Topical Cream with USP, improved bio-availability versus existing testosterone topical gels leads to lower doses and therefore less side effects. No drying time required prior to dressing and lower COGS versus competition. Treatment for males suffering from hypogonadism, women suffering from sexual dysfunction. Exclusive licences are available. Also patented.(ID: MC-0176)</p> <p>Countries: individual countries worldwide</p>

166.	Syphilis	<p>Exclusive licence for the treatment of syphilis is available. It is a niche product and a growing market because of the refugees and immigrants. (ID: MC-0387)</p> <p>Countries: individual countries on request</p>
167.	Food supplement	<p>For a food supplement that promotes male fertility a licence is available. (ID: MC-0360)</p> <p>Countries: worldwide</p>
168.	Erectile dysfunction	<p>An exclusive licence is available for the treatment of erectile dysfunction. The active ingredient is well known but the dosage form is unique on the market. It is possible for licences to use their own brand name. (ID: MC-0310)</p> <p>Countries: individual countries worldwide</p>

Registrations/Dossiers*		
169.	Cardiovascular	<p>A small package of MAs for high blood pressure, heart failure and arrhythmia are available. (ID: MC-0420)</p> <p>Countries: Malta</p>
170.	Registration package	<p>A package of generic registrations in CNS, Pain, Cardiovascular, etc. is available in Spain. (ID: MC-0417)</p> <p>Countries: Spain</p>
171.	Infection	<p>A CTD dossier for the treatment of acute and chronic infections is offered. Product underlies production binding. (ID: MC-0425)</p> <p>Countries: on request</p>
172.	Pain	<p>MAs for severe pain treatment are available. (ID: MC-0433)</p> <p>Countries: Germany, Switzerland and Austria</p>
173.	OTC cold	<p>Exclusive OTC approval for Germany available in the area of cold treatment. It is an herbal cough syrup with very good taste and therefore suitable for children. (ID: MC-0393)</p> <p>Countries: Germany</p>
174.	OTC cough	<p>Exclusive OTC approval in the form of oral films for the treatment of cough is available. (ID: MC-0394)</p> <p>Countries: Germany</p>
175.	OTC depression	<p>An exclusive OTC approval for the treatment of depression and anxiety is available. (ID: MC-0395)</p> <p>Countries: Germany</p>
176.	OTC pain	<p>An exclusive approval that helps with some complaints such as Osteoarthritis, rheumatism and back pain is available. (ID: MC-0396)</p> <p>Countries: France</p>
177.	OTC approvals	<p>Various OTC approvals are available. (ID: MC-0397)</p> <p>Countries: UK</p>

178.	Existing registrations up for sale	<p>A number of existing approvals are up for sale in Germany including citalopram, naproxen, a fentanyl transdermal patch, fluoxetine HCL, pantoprazole, a tramadol solution for injection ...</p> <p>Countries: Germany</p>
179.	Calcium acetate	<p>Two Marketing Authorisations of calcium acetate are for sale. (ID: MC-0283)</p> <p>Countries: UK, Italy and Spain</p>
180.	Dossiers	<p>Several dossiers are available (with supply):</p> <ul style="list-style-type: none"> Benfotiamine Daptomycin Leuprorelin Goserelin Donepezil + Memantine Ezetimibe + Rosuvastatin Clopidogrel + ASA Lacosamide Ulipristel Acetate Desmopressin ODT Enzalutamide Fentanyl tablets Fingolimed Lorazepam injection Naloxone ampoules Piperacillin/Tazobactam injection powder Zolpidem (with faster effect) and many more (ID: MC-0328) <p>Countries: on request</p>
181.	Registrations/Dossiers	<p>Please contact us to find out whether the marketing authorization or dossier you are looking for is in our database. Information about the registration status and countries you are interested in is also very useful to help narrow the search.</p> <p>Countries: on request</p>

* Availability of products is subject to patent restrictions in countries where patents are in force!

III. Search projects on behalf of our clients

On behalf of our clients, we are looking for the following acquisition and cooperation opportunities. We welcome any suggestions or offers. All information shall be treated as strictly confidential.

Project		Short Description
182.	Nephrology/CNS	<p>On behalf of our innovative client, we are looking for prescription products / licences with a certain USP (unique selling proposition) in the field of nephrology and CNS! Our client would like to use its established sales force in this target group. All suggestions are welcome. Co-promotion is also a possible option. (ID: MC-0445)</p> <p>Countries: Germany, Austria and Switzerland</p>
183.	Hospital / Specialty Care	<p>We are looking for companies and products with existing sales in the hospital sector on behalf of our innovative global client. Preferably no generic targets but rather branded products with a USP in the prescription area. Turnover up to 500 million euros worldwide possible. Preferably in Eastern Europe and / or Scandinavia. All offers and hints are welcome. (ID: MC-0446)</p> <p>Countries: worldwide</p>
184.	OTC Products	<p>On behalf of our client in Germany we search for OTC products with existing sales. Our client has an established sales force in the pharmacy and wants to further expand his portfolio. All offers or hints are welcome! (ID: MC-0447)</p> <p>Countries: Germany</p>
185.	Urology/CNS	<p>On behalf of our Spanish client we are looking for products / licences with a certain unique selling point or at least limited direct competition in the field of urology and CNS. Our client is excellently established in this segment and has his own well experienced field force. He market his own products as well as licensed products very successfully and has a very good track record! All offers and hints are welcome. (ID: MC-0448)</p> <p>Countries: Spain</p>

Project		Short Description
186.	Niche products	<p>We from Dr. Newzella are always searching for niche products or licences in all kind of indications Rx or OTC for our clients. If you have something in your pipeline we are happy to offer it to our clients. This is free of charge for you. We are flexible, fast and target oriented and look for a Win-Win-Position for both sides. (ID: MC-0449)</p> <p>Countries: worldwide</p>
187.	Mesalazine tablet 2g, 3g	<p>We are searching on behalf of our international client for a licence/dossier of Mesalazine tablet 2g, 3g for certain territories in Europe and world-wide. Any help is appreciated!</p> <p>Countries: Europe</p>

Dr. Newzella GmbH

Since the foundation of our consultancy business in 1980, we have been specializing in the pharmaceutical and health care industry. We provide services within merger & acquisition as well as product & licensing.

Please visit our website at www.newzella.com to learn more about our company.

If you should be offering or looking for acquisition or cooperation opportunities concerning:

- companies, products, business units etc.
- brand name products with established sales,
- R&D projects between preclinical and phase III,
- marketing or licensing rights,

then we can help you to find qualified partners at national/international or global level.

We provide a wide range of services. We accompany the whole of the transaction process from identifying potential partners to the signing of the contract and always in accordance with the wishes and expectations of our clients.

Make the most of our knowledge. We are there to help you.

Dr. Christoph Newzella
Managing Partner & Director MC
Dr. Newzella Consulting - since 1980
Tel.: +49 (0) 2508 9942-113
Fax.: +49 (0) 2508 9942-200
Mob.: +49 (0) 171-28 54 86 0
christoph.newzella@newzella.com

Dr. Matthias Newzella
Managing Partner
Dr. Newzella Consulting - since 1980
Tel.: +49 (0) 2508 9942-102
Fax.: +49 (0) 2508 9942-200
Mob.: +49 (0) 171-64 07 74 0
matthias.newzella@newzella.com

Detlev Heyne
Senior Consultant
Dr. Newzella Consulting - since 1980
Tel.: +49 (0) 40 23 99 45 23
Fax.: +49 (0) 2508 9942-200
Mob.: +49 (0) 172-64 76 28 1
detlev.heyne@newzella.com

Katrin Brandhove
Executive Assistant & Project Manager
Dr. Newzella Consulting - since 1980
Tel.: +49 (0) 2508 9942-136
Fax.: +49 (0) 2508 9942-200
katrin.brandhove@newzella.com